scFv(CD20)-OX40-CD3zeta CAR-T Lentivirus

The scFv(CD20)-OX40-CD3zeta CAR-T Lentivirus represents a viral vector system for delivering second-generation chimeric antigen receptor (CAR) constructs. These lentiviral particles offer several key advantages as a gene delivery vehicle: high transduction efficiency across both dividing and non-dividing cells, stable genomic integration enabling long-term CAR expression, and a favorable safety profile with reduced immunogenicity compared to other viral vectors. The lentiviral backbone has been optimized to minimize the risk of insertional mutagenesis while maintaining high viral titers. This particular construct incorporates three critical functional domains: an anti-CD20 single-chain variable fragment (scFv) for target recognition, the OX40 costimulatory domain to enhance T cell persistence and antitumor activity, and the CD3zeta signaling domain to initiate T cell activation. The modular design allows for efficient packaging of the large CAR transgene while preserving viral particle integrity.

This CAR-T lentivirus has significant therapeutic applications in hematologic malignancies, particularly for B-cell lymphomas and leukemias expressing CD20. Clinical applications focus on engineering autologous T cells to target CD20-positive tumors while overcoming common limitations of first-generation CAR-T therapies. The inclusion of OX40 addresses T cell exhaustion issues, potentially improving the durability of responses. Preclinical studies demonstrate robust in vitro and in vivo activity against CD20+ tumor models with enhanced proliferation and cytokine production compared to CD28-containing constructs. Additional potential applications include combination therapies with checkpoint inhibitors, bispecific antibody approaches, and treatment of autoimmune conditions through targeted B-cell depletion.